Head to Head Comparison: Vivos Therapeutics (VVOS) versus The Competition

Vivos Therapeutics (NASDAQ:VVOS) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Vivos Therapeutics to related businesses based on the strength of its dividends, earnings, risk, institutional ownership, profitability, valuation and analyst recommendations.

Valuation and Earnings

This table compares Vivos Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	-$21.17 million	-0.05
Vivos Therapeutics Competitors	$1.89 billion	$136.85 million	12.52

Vivos Therapeutics’ competitors have higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for Vivos Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
Vivos Therapeutics Competitors	4290	10573	18352	830	2.46

Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 3,144.50%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.12%. Given Vivos Therapeutics’ higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than its competitors.

Volatility and Risk

Vivos Therapeutics has a beta of 6.37, meaning that its share price is 537% more volatile than the S&P 500. Comparatively, Vivos Therapeutics’ competitors have a beta of 2.57, meaning that their average share price is 157% more volatile than the S&P 500.

Profitability

This table compares Vivos Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Vivos Therapeutics Competitors	-304.10%	-178.81%	-22.11%

Insider and Institutional Ownership

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 1.4% of Vivos Therapeutics shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Vivos Therapeutics competitors beat Vivos Therapeutics on 10 of the 13 factors compared.

About Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.